BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 26422359)

  • 1. Suspected non-AD pathology in mild cognitive impairment.
    Wisse LEM; Butala N; Das SR; Davatzikos C; Dickerson BC; Vaishnavi SN; Yushkevich PA; Wolk DA;
    Neurobiol Aging; 2015 Dec; 36(12):3152-3162. PubMed ID: 26422359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer Disease Signature Neurodegeneration and APOE Genotype in Mild Cognitive Impairment With Suspected Non-Alzheimer Disease Pathophysiology.
    Schreiber S; Schreiber F; Lockhart SN; Horng A; Bejanin A; Landau SM; Jagust WJ;
    JAMA Neurol; 2017 Jun; 74(6):650-659. PubMed ID: 28319241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. White matter hyperintensities and amyloid are independently associated with entorhinal cortex volume among individuals with mild cognitive impairment.
    Guzman VA; Carmichael OT; Schwarz C; Tosto G; Zimmerman ME; Brickman AM;
    Alzheimers Dement; 2013 Oct; 9(5 Suppl):S124-31. PubMed ID: 23375566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease.
    Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S;
    Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology.
    Chung JK; Plitman E; Nakajima S; Caravaggio F; Iwata Y; Gerretsen P; Kim J; Takeuchi H; Shinagawa S; Patel R; Chakravarty MM; Graff-Guerrero A;
    J Alzheimers Dis; 2017; 58(3):747-762. PubMed ID: 28505977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
    Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
    Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amyloid negativity in patients with clinically diagnosed Alzheimer disease and MCI.
    Landau SM; Horng A; Fero A; Jagust WJ;
    Neurology; 2016 Apr; 86(15):1377-1385. PubMed ID: 26968515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining SNAP by cross-sectional and longitudinal definitions of neurodegeneration.
    Wisse LEM; Das SR; Davatzikos C; Dickerson BC; Xie SX; Yushkevich PA; Wolk DA;
    Neuroimage Clin; 2018; 18():407-412. PubMed ID: 29487798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study.
    Burnham SC; Bourgeat P; Doré V; Savage G; Brown B; Laws S; Maruff P; Salvado O; Ames D; Martins RN; Masters CL; Rowe CC; Villemagne VL;
    Lancet Neurol; 2016 Sep; 15(10):1044-53. PubMed ID: 27450471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Education on Alzheimer's Disease-Related Neuroimaging Biomarkers in Healthy Controls, and Participants with Mild Cognitive Impairment and Alzheimer's Disease: A Cross-Sectional Study.
    Wada M; Noda Y; Shinagawa S; Chung JK; Sawada K; Ogyu K; Tarumi R; Tsugawa S; Miyazaki T; Yamagata B; Graff-Guerrero A; Mimura M; Nakajima S;
    J Alzheimers Dis; 2018; 63(2):861-869. PubMed ID: 29689728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum.
    Kuhn E; Perrotin A; La Joie R; Touron E; Dautricourt S; Vanhoutte M; Vivien D; de La Sayette V; Chételat G;
    Neurology; 2023 Jun; 100(24):e2454-e2465. PubMed ID: 37085328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oh brother, where art tau? Amyloid, neurodegeneration, and cognitive decline without elevated tau.
    McCollum LE; Das SR; Xie L; de Flores R; Wang J; Xie SX; Wisse LEM; Yushkevich PA; Wolk DA;
    Neuroimage Clin; 2021; 31():102717. PubMed ID: 34119903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic correlates of reserve and resilience in MCI due to Alzheimer's Disease (AD).
    Bauckneht M; Chincarini A; Piva R; Arnaldi D; Girtler N; Massa F; Pardini M; Grazzini M; Efeturk H; Pagani M; Sambuceti G; Nobili F; Morbelli S
    Alzheimers Res Ther; 2018 Apr; 10(1):35. PubMed ID: 29615111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive reserve and clinical progression in Alzheimer disease: A paradoxical relationship.
    van Loenhoud AC; van der Flier WM; Wink AM; Dicks E; Groot C; Twisk J; Barkhof F; Scheltens P; Ossenkoppele R;
    Neurology; 2019 Jul; 93(4):e334-e346. PubMed ID: 31266904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Underlying Biological Processes in Mild Cognitive Impairment: Amyloidosis Versus Neurodegeneration.
    Santana I; Baldeiras I; Santiago B; Duro D; Freitas S; Pereira MT; Almeida MR; Oliveira CR
    J Alzheimers Dis; 2018; 64(s1):S647-S657. PubMed ID: 29562515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment.
    King-Robson J; Wilson H; Politis M;
    J Alzheimers Dis; 2021; 82(2):541-560. PubMed ID: 34057079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. White matter hyperintensities and cognition across different Alzheimer's biomarker profiles.
    Lam S; Lipton RB; Harvey DJ; Zammit AR; Ezzati A;
    J Am Geriatr Soc; 2021 Jul; 69(7):1906-1915. PubMed ID: 33891712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.